Recently, Rongzhong officially released its 2025-2026 Annual Industry Investment Rankings. EFUNG Capital was honored as one of the "Best Investment Institutions in China's Healthcare Sector 2025-2026," and CEO Zhu Pai was named one of the "Best Investment Figures in China's Healthcare Sector 2025-2026."
The 2026 Government Work Report, for the first time, places the biopharmaceutical industry on par with integrated circuits, aerospace, and low-altitude economy, explicitly designating it as an "emerging pillar industry." This is not merely an iterative update in policy wording, but a fundamental shift in the nation's approach to industrial upgrading and economic transition. For the capital market, investment is no longer about chasing the next hot trend—it is about moving in deep resonance and alignment with the real economy within a structured institutional framework.
The ranking was compiled by Rongzhong Research, leveraging its proprietary database and professional research team. The selection process involved questionnaire surveys, interviews, indicator calculations, data verification, and comprehensive scoring. Investment institutions were evaluated across multiple dimensions using a combination of quantitative and qualitative methodologies, resulting in one of the most influential comprehensive rankings in China's equity and industrial investment landscape. The results were officially announced at the "2026 China Industrial Investment Summit."
Looking ahead, EFUNG Capital remains steadfast in its long-term commitment to early-stage biopharmaceutical investing, closely aligning with national strategic industrial development priorities and continuing to fulfill its core mission of channeling industrial capital into the real economy.
Disclaimer
This material represents the views of the Company based on currently available public information and data provided by portfolio companies. It does not constitute investment advice, medical advice, or any guarantee of specific enterprise performance. Investing involves risks; please act with caution. Readers are advised to make independent judgments based on publicly available information. Unauthorized reproduction or commercial use is prohibited.